Rising Precision Oncology Demand and Technological Advances Drive Growth in the Global Genomic Biomarker Market

Genomic biomarker market was valued at $8.4 billion in 2024 and is projected to reach $41.7 billion by 2035, growing at a CAGR of 15.8% during the forecast period (2025–2035). The growing demand for precision oncology and targeted therapies is driving the adoption of genomic biomarkers, enabling clinicians to tailor treatments based on individual patient profiles. Genomic biomarkers are increasingly used for early diagnosis, prognosis, and therapy selection, improving clinical outcomes in cancer care.

Browse the full report description of “Genomic Biomarker Market Size, Share & Trends Analysis Report by Type (Predictive Biomarkers, and Prognostic Biomarkers) by Disease Indication (Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, and Others), and by End-User (Diagnostic and Research Laboratories, Hospitals, and Others) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/genomic-biomarkers-market

At the same time, advancements in technologies such as next-generation sequencing (NGS), circulating tumour DNA (ctDNA), single-cell analysis, and bioinformatics are lowering costs and expanding the utility of genomic testing. Supportive regulatory frameworks, favourable reimbursement policies, and strategic pharma partnerships are further accelerating commercialization and global market growth.

Real-Life Developments Highlight the Growing Importance of Genomic Biomarkers

• 2025: Advances in single-cell analysis and bioinformatics platforms improved the accuracy and cost-effectiveness of genomic biomarker tests, fostering adoption in both clinical and research settings across North America, Europe, and Asia-Pacific.
• 2024: The American Cancer Society reported that precision oncology approaches using genomic biomarkers significantly improved survival rates in patients with lung, breast, and colorectal cancers, highlighting their clinical utility in targeted therapies.
• 2025: A study published by the National Cancer Institute (NCI) noted that adoption of next-generation sequencing (NGS) and circulating tumour DNA (ctDNA) testing increased across U.S. and European hospitals, enabling earlier detection and more personalized treatment strategies.

Innovation and Strategic Partnerships in the Genomic Biomarker Market

Industry players are investing heavily in advanced sequencing technologies, bioinformatics platforms, and high-throughput genomic testing to enhance accuracy, reduce turnaround times, and lower costs. Companies are also developing integrated solutions for clinical and research applications, supporting precision oncology and personalized medicine initiatives.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Type
• Disease Indication
• End-User

• Competitive Landscape – Bio-Rad Laboratories Inc., Hoffmann-La Roche Ltd., Illumina, QIAGEN and Thermo Fisher Scientific.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Genomic Biomarker Market Report Segment

By Type

• Predictive Biomarkers
• Prognostic Biomarkers

By Disease Indication

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Renal Disorders
• Others

By End-User

• Diagnostic and Research Laboratories
• Hospitals
• Others

Global Genomic Biomarker Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/genomic-biomarkers-market